Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PopS-HF Trial
2025-520660-18-00Phase 4Authorised
- Sponsor
- Policlinico San Donato
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan, dapagliflozin, empagliflozin, losartan, candesartan and 20 more in heart failure (HF) and Acute Heart Failure (AHF) (2 arms), sponsored by Policlinico San Donato. Primary endpoints: Primary endpoint (retrospective study) and Primary endpoint (prospective study). Planned start May 2026; status: authorised.
02
Drugs
sacubitril + valsartandapagliflozinempagliflozinlosartancandesartan
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2025-520660-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520660-18-00.